Issues complicating precision dosing for factor VIII prophylaxis.

[1]  S. Kitchen,et al.  Measuring FVIII activity of glycopegylated recombinant factor VIII, N8‐GP, with commercially available one‐stage clotting and chromogenic assay kits: a two‐centre study , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[2]  P. Turecek,et al.  A world‐wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[3]  S. Kitchen,et al.  Recombinant to modified factor VIII and factor IX – chromogenic and one‐stage assays issues , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  M. Makris,et al.  Factor VIII assay variability in postinfusion samples containing full length and B‐domain deleted FVIII , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[5]  T. Orfeo,et al.  Activation, activity and inactivation of factor VIII in factor VIII products , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[6]  D. Perry,et al.  A computer‐based model to assess costs associated with the use of factor VIII and factor IX one‐stage and chromogenic activity assays , 2016, Journal of thrombosis and haemostasis : JTH.

[7]  Y. Katterle,et al.  BAY 81‐8973, a full‐length recombinant factor VIII: results from an International comparative laboratory field study , 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

[8]  J. Oldenburg,et al.  A critical appraisal of one‐stage and chromogenic assays of factor VIII activity , 2016, Journal of thrombosis and haemostasis : JTH.

[9]  Wei Jia,et al.  The influence of gut microbiota on drug metabolism and toxicity , 2016, Expert opinion on drug metabolism & toxicology.

[10]  N. Curry,et al.  Thrombin generation assay triggered with tissue factor or factor XIa in patients with severe haemophilia A , 2016 .

[11]  D. Motto,et al.  Diagnostic approach to von Willebrand disease. , 2015, Blood.

[12]  J. Oldenburg,et al.  Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans. , 2015, Blood.

[13]  A. Hillarp,et al.  One‐stage vs. chromogenic assays in haemophilia A , 2015, European journal of haematology.

[14]  D. Kokaridas,et al.  The Effect of Aerobic and Weight Lifting Exercise on Blood Clotting , 2014 .

[15]  Katie Bergstrom,et al.  Co‐inheritance of mild hemophilia A and heterozygosity for type 2N von Willebrand disease: A diagnostic and therapeutic challenge , 2014, Pediatric blood & cancer.

[16]  L. Valentino.  Considerations in individualizing prophylaxis in patients with haemophilia A , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[17]  K. Moser,et al.  Chromogenic factor VIII activity assay , 2014, American journal of hematology.

[18]  V. Laux,et al.  Evaluation of the activated partial thromboplastin time assay for clinical monitoring of PEGylated recombinant factor VIII (BAY 94‐9027) for haemophilia A , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  M. Makris,et al.  Assaying FVIII activity: one method is not enough, and never was , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[20]  M. Carcao.  Changing paradigm of prophylaxis with longer acting factor concentrates , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[21]  R. Weinshilboum,et al.  Pharmacometabolomics: Implications for Clinical Pharmacology and Systems Pharmacology , 2014, Clinical pharmacology and therapeutics.

[22]  J. Oldenburg,et al.  Haemophilia A mutations in patients with non-severe phenotype associated with a discrepancy between one-stage and chromogenic factor VIII activity assays , 2014, Thrombosis and Haemostasis.

[23]  B. Konkle,et al.  Comparative field study evaluating the activity of recombinant factor VIII Fc fusion protein in plasma samples at clinical haemostasis laboratories , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[24]  M. Makris,et al.  Specific and global coagulation assays in the diagnosis of discrepant mild hemophilia A , 2013, Haematologica.

[25]  J. Dodt,et al.  Recommendations on the potency labelling of factor VIII and factor IX concentrates , 2013, Journal of thrombosis and haemostasis : JTH.

[26]  E. Duncan,et al.  Diagnostic Testing for Mild Hemophilia A in Patients with Discrepant One-Stage, Two-Stage, and Chromogenic Factor VIII:C Assays , 2013, Seminars in Thrombosis & Hemostasis.

[27]  M. Carrington,et al.  F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[28]  J. Mahlangu,et al.  Guidelines for the management of hemophilia , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[29]  A. Reininger,et al.  The principles of PK-tailored prophylaxis , 2013, Hämostaseologie.

[30]  O. Walter,et al.  Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII. , 2012, Thrombosis research.

[31]  M. Cnossen,et al.  Age dependency of coagulation parameters during childhood and puberty , 2012, Journal of thrombosis and haemostasis : JTH.

[32]  Rob Knight,et al.  Defining the human microbiome. , 2012, Nutrition reviews.

[33]  K. Mann,et al.  The influence of prophylactic factor VIII in severe haemophilia A , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[34]  L. Valentino,et al.  A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management , 2012, Journal of thrombosis and haemostasis : JTH.

[35]  C. Ternisien,et al.  The use of the new ReFacto AF Laboratory Standard allows reliable measurement of FVIII:C levels in ReFacto AF mock plasma samples by a one‐stage clotting assay , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[36]  P. Allavena,et al.  Identification of thrombin-like activity in ovarian cancer associated ascites and modulation of multiple cytokine networks , 2011, Thrombosis and Haemostasis.

[37]  D. Viuff,et al.  International comparative field study of N8 evaluating factor VIII assay performance , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[38]  M. Trossaërt,et al.  Prevalence, biological phenotype and genotype in moderate/mild hemophilia A with discrepancy between one‐stage and chromogenic factor VIII activity , 2011, Journal of thrombosis and haemostasis : JTH.

[39]  M. Morfini,et al.  Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[40]  J. Oldenburg,et al.  Discrepancy between one-stage and chromogenic factor VIII activity assay results can lead to misdiagnosis of haemophilia A phenotype , 2010, Hämostaseologie.

[41]  C. Négrier,et al.  New developments in laboratory diagnosis and monitoring , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[42]  S. Björkman.  Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[43]  D. Venkateswarlu.  Structural investigation of zymogenic and activated forms of human blood coagulation factor VIII: a computational molecular dynamics study , 2010, BMC Structural Biology.

[44]  B. Verbruggen,et al.  The between-Laboratory Variation of Factor VIII Inhibitor Testing: The Experience of the External Quality Assessment Program of the ECAT Foundation , 2009, Seminars in thrombosis and hemostasis.

[45]  S. Kitchen,et al.  Interlaboratory variation in factor VIII:C inhibitor assay results is sufficient to influence patient management: data from the UK national quality external assessment scheme for blood coagulation. , 2009, Seminars in thrombosis and hemostasis.

[46]  H. Ehrlich,et al.  Development of a plasma- and albumin -free recombinant von Willebrand factor , 2009, Hämostaseologie.

[47]  L. Almasy,et al.  Inhibitors of factor VIII in black patients with hemophilia. , 2009, The New England journal of medicine.

[48]  K. Mann,et al.  Potency and mass of factor VIII in FVIII products , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[49]  J. Ingerslev,et al.  Assay discrepancy in mild haemophilia A: entire population study in a National Haemophilia Centre , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[50]  G. Lippi,et al.  One-stage clotting versus chromogenic assays for assessing recombinant factor VIII: two faces of a haemostasis coin. , 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[51]  A. Cid,et al.  One‐stage and chromogenic FVIII:C assay discrepancy in mild haemophilia A and the relationship with the mutation and bleeding phenotype , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[52]  V D Schmith,et al.  Effects of Inflammation on Pharmacokinetics/Pharmacodynamics: Increasing Recognition of Its Contribution to Variability in Response , 2008, Clinical pharmacology and therapeutics.

[53]  M. Carcao,et al.  Different clinical phenotype in triplets with haemophilia A , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[54]  P. Mannucci,et al.  ReFacto® 1 and Advate® 2 : a single‐dose, randomized, two‐period crossover pharmacokinetics study in subjects with haemophilia A , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[55]  D. Quinn,et al.  In vitro kinetics of factor VIII activity in patients with mild haemophilia A and a discrepancy between one‐stage and two‐stage factor VIII assay results , 2007, British journal of haematology.

[56]  S. Béguin,et al.  New approaches for measuring coagulation , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[57]  M. Morfini,et al.  Accuracy of FVIII:C assay by one‐stage method can be improved using hemophilic plasma as diluent , 2006, Journal of thrombosis and haemostasis : JTH.

[58]  P. Fay.  Factor VIII Structure and Function , 2006, International journal of hematology.

[59]  C. Esmon.  The interactions between inflammation and coagulation , 2005, British journal of haematology.

[60]  B. Dahlback.  Regulation of Blood Coagulation by the Protein C Anticoagulant Pathway : novel insights into structure-function relationships and molecular recognition , 2005 .

[61]  J. Ingerslev,et al.  Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one‐stage clotting assays , 2004, Journal of thrombosis and haemostasis : JTH.

[62]  P. Mannucci,et al.  A multicenter pharmacokinetic study of the B‐domain deleted recombinant factor VIII concentrate using different assays and standards , 2003, Journal of thrombosis and haemostasis : JTH.

[63]  J. Smith,et al.  Effects of strenuous exercise on haemostasis , 2003, British journal of sports medicine.

[64]  T. Barrowcliffe,et al.  Standardization of FVIII & FIX assays , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[65]  W. Chandler,et al.  Comparison of three methods for measuring factor VIII levels in plasma. , 2003, American journal of clinical pathology.

[66]  S. Björkman.  Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[67]  A. Goodeve,et al.  The Molecular Basis of Hemophilia A: Genotype-Phenotype Relationships and Inhibitor Development , 2003, Seminars in thrombosis and hemostasis.

[68]  T. Barrowcliffe,et al.  Coagulation and Chromogenic Assays of Factor VIII Activity: General Aspects, Standardization, and Recommendations , 2002, Seminars in thrombosis and hemostasis.

[69]  M. Mikaelsson,et al.  Assaying the circulating factor VIII activity in hemophilia A patients treated with recombinant factor VIII products. , 2002, Seminars in thrombosis and hemostasis.

[70]  M. Mikaelsson,et al.  Measurement of factor VIII activity of B-domain deleted recombinant factor VIII. , 2001, Seminars in hematology.

[71]  F. Rosendaal,et al.  Definitions in Hemophilia , 2001, Thrombosis and Haemostasis.

[72]  P. Lenting,et al.  The life cycle of coagulation factor VIII in view of its structure and function. , 1998, Blood.

[73]  E. Rodríguez‐Merchán.  Pathogenesis, early diagnosis, and prophylaxis for chronic hemophilic synovitis. , 1997, Clinical orthopaedics and related research.

[74]  J. Raboud,et al.  Effect of thromboplastin and coagulometer interaction on the precision of the International Normalised Ratio. , 1995, Journal of clinical pathology.

[75]  T. Barrowcliffe,et al.  Evaluation of Factor Vlll Deficient Plasmas , 1993, Thrombosis and Haemostasis.

[76]  P. Fay.  Factor VIII Structure and Function , 1993, Thrombosis and Haemostasis.

[77]  Y. Nemerson,et al.  Measurement of basal levels of factor VIIa in hemophilia A and B patients. , 1992, Blood.

[78]  A. Parquet‐Gernez,et al.  Validation of a Procedure for Potency Assessing of a High Purity Factor VIII Concentrate -Comparison of Different Factor VIII Coagulant Assays and Effect of Prediluent , 1990, Thrombosis and Haemostasis.

[79]  C. Rothschild,et al.  Preparation of factor-VIII-depleted plasma with antibodies and its use for the assay of factor VIII. , 1990, Haemostasis.

[80]  J. Over.  Methodology of the one-stage assay of Factor VIII (VIII:C). , 2009, Scandinavian journal of haematology. Supplementum.

[81]  Seghatchian Mj.  A new approach to the determination of coagulation factors using chromogenic substrates. , 1978 .

[82]  M. Seghatchian.  A new approach to the determination of coagulation factors using chromogenic substrates. , 1978, Medical laboratory sciences.

[83]  E. Vesell,et al.  Genetic Control of Drug Levels in Man: Antipyrine , 1968, Science.